Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences
暂无分享,去创建一个
[1] B. Brownell,et al. The distribution of plaques in the cerebrum in multiple sclerosis , 1962, Journal of neurology, neurosurgery, and psychiatry.
[2] W. Mcdonald,et al. The longstanding MS lesion. A quantitative MRI and electron microscopic study. , 1991, Brain : a journal of neurology.
[3] J. Coyle,et al. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies , 1991, Neuroscience.
[4] Stephen M. Rao,et al. Cognitive dysfunction in multiple sclerosis. , 1991, Neurology.
[5] J. Neale,et al. Immunohistochemical localization of N-acetylaspartate in rat brain. , 1991, Neuroreport.
[6] M Noble,et al. Specific Expression of N‐Acetylaspartate in Neurons, Oligodendrocyte‐Type‐2 Astrocyte Progenitors, and Immature Oligodendrocytes In Vitro , 1992, Journal of neurochemistry.
[7] Scott T. Brady,et al. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells , 1992, Cell.
[8] Roland Martin,et al. Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.
[9] G J Barker,et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.
[10] P. Matthews,et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis , 1994, Annals of neurology.
[11] D. Arnold,et al. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo , 1994, Neurology.
[12] R. Paul,et al. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI) , 1995, Neurology.
[13] A. Thompson,et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. , 1995, Brain : a journal of neurology.
[14] P. Matthews,et al. Chemical pathology of acute demyelinating lesions and its correlation with disability , 1995, Annals of neurology.
[15] A J Thompson,et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.
[16] A. Thompson,et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. , 1996, Brain : a journal of neurology.
[17] R. Hohlfeld,et al. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. , 1997, Brain : a journal of neurology.
[18] V. Perry,et al. Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.
[19] J S Wolinsky,et al. Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis , 1998, Annals of neurology.
[20] K. Nave,et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. , 1998, Science.
[21] S. Waxman. Demyelinating diseases--new pathological insights, new therapeutic targets. , 1998, The New England journal of medicine.
[22] P M Matthews,et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.
[23] J. Clark,et al. N-Acetyl Aspartate: A Marker for Neuronal Loss or Mitochondrial Dysfunction , 1998, Developmental Neuroscience.
[24] P M Matthews,et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.
[25] P. Matthews,et al. Putting Magnetic Resonance Spectroscopy Studies in Context: Axonal Damage and Disability in Multiple Sclerosis , 1998, Seminars in neurology.
[26] W. Brück,et al. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions , 1998, Multiple sclerosis.
[27] R. Rudick,et al. Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.
[28] Virginia M. Y. Lee,et al. Myelin-Associated Glycoprotein Is a Myelin Signal that Modulates the Caliber of Myelinated Axons , 1998, The Journal of Neuroscience.
[29] F. Barkhof,et al. Cortical lesions in multiple sclerosis. , 1999, Brain : a journal of neurology.
[30] V. Stevenson,et al. Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis , 1999, Multiple sclerosis.
[31] H. Lassmann,et al. Axonal Pathology in Multiple Sclerosis. A Historical Note , 1999, Brain pathology.
[32] R. Rudick,et al. Neurodegeneration in Multiple Sclerosis: Relationship to Neurological Disability , 1999 .
[33] Ganter,et al. Spinal cord axonal loss in multiple sclerosis: a post‐mortem study , 1999, Neuropathology and applied neurobiology.
[34] Bruce D. Trapp,et al. Axonal pathology in myelin disorders , 1999, Journal of neurocytology.
[35] R. Herndon,et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis , 1999, Neurology.
[36] R. Rudick,et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.
[37] F. Barkhof,et al. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.
[38] M Filippi,et al. Normal-appearing white matter changes in multiple sclerosis: the contribution of magnetic resonance techniques , 1999, Multiple sclerosis.
[39] C Confavreux,et al. Relapses and progression of disability in multiple sclerosis. , 2000, The New England journal of medicine.
[40] P M Matthews,et al. Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. , 2000, Archives of neurology.
[41] M. Palkovits,et al. Axonal changes in chronic demyelinated cervical spinal cord plaques. , 2000, Brain : a journal of neurology.
[42] R. Kinkel,et al. A Wallerian degeneration pattern in patients at risk for MS , 2000, Neurology.
[43] J H Simon,et al. A longitudinal study of T1 hypointense lesions in relapsing MS , 2000, Neurology.
[44] R I Grossman,et al. Total brain N-acetylaspartate , 2000, Neurology.
[45] H. Lassmann,et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. , 2000, The American journal of pathology.
[46] K. Bhakoo,et al. In Vitro Expression of N‐Acetyl Aspartate by Oligodendrocytes , 2000, Journal of neurochemistry.
[47] P M Matthews,et al. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. , 2000, Brain : a journal of neurology.
[48] W. Brück,et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. , 2000, Brain : a journal of neurology.
[49] M. Blinkenberg,et al. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS , 2000, Neurology.
[50] S. Croul,et al. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis , 2000, Journal of the Neurological Sciences.
[51] P M Matthews,et al. Correlating magnetic resonance imaging markers of axonal injury and demyelination in motor impairment secondary to stroke and multiple sclerosis. , 2000, Magnetic resonance imaging.
[52] Nikos Evangelou,et al. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis , 2000, Annals of neurology.
[53] R. Rudick,et al. Neurological disability correlates with spinal cord axonal loss and reduced N‐acetyl aspartate in chronic multiple sclerosis patients , 2000, Annals of neurology.
[54] D. Pitt,et al. Glutamate excitotoxicity in a model of multiple sclerosis , 2000, Nature Medicine.